Lantern Pharma: Revolutionizing the Future of Oncology with AI and Machine Learning
Apr. 8, 2022
Lantern Pharma (NASDAQ: LTRN) is a clinical stage oncology-focused company who is harnessing the power of Artificial Intelligence and Genomics to develop precision cancer therapies. By leveraging RADR®, Lantern's proprietary big data engine, more effective cancer treatments can be developed and delivered to the right group of patients at a faster rate and for a fraction of the cost. RADR® identifies genetic signature patterns that underpin the identification of patients for whom Lantern's portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. This is the future of precision medicine and Lantern is at the forefront of AI driven transformation that will change the lives of cancer patients. Visit https://www.ltrninfo.com/ to learn more.
